Q32 Bio Completes $55 Million Private Placement
Q32 Bio announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors for the private placement of common stock and pre-funded warrants for an aggregate of approximately $55M. In this private placement, the company has agreed to issue and sell to such institutional and accredited investors (i) 6,725,000 shares of the company's common stock, at a price of $8.00 per share, and (ii) pre-funded warrants to purchase 150,000 shares of common stock, at a price of $7.9999 per pre-funded warrant, which equals the per share price of $8.00 less the exercise price $0.0001 for such pre-funded warrant. The pre-funded warrants are immediately exercisable and will expire when exercised in full. Q32 Bio anticipates the gross proceeds from the private placement to be approximately $55M, before deducting fees to the placement agents and other offering expenses payable by the company. The private placement is expected to close on May 28, subject to customary closing conditions. The private placement is being led by BVF Partners L.P., with participation from RA Capital Management, OrbiMed, and Atlas Venture. Morgan Stanley acted as lead placement agent and Oppenheimer & Co. acted as a placement agent in the private placement.
